Fig. 6.

Pharmacokinetics of γ3-targeted nanocarriers in mice. A, anesthetized C57BL/6 mice were injected intravenously with γ3/¹²⁵I-IgG NCs or nonspecific control γ3S/¹²⁵I-IgG NCs. The level of the carriers accumulated in liver and lung was assessed 30 min after injection and expressed as the percentage of the ID (%ID). B, accumulation of γ3/¹²⁵I-IgG NCs in the liver and lung was compared with that of anti-ICAM NCs (clone YN1). C, the circulating level of carriers, assessed at 1 to 2, 15, and 30 min after injection, is shown. Data are mean ± S.E.M. (n ≥3 mice). Asterisks compare γ3 NCs to γ3S NCs (A) and γ3 NCs to anti-ICAM NCs (B). *, p < 0.05; **, p < 0.01; ***, p < 0.001, by Student's t test.